Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Viral hepatitis more deadly than HIV in Europe

Viral hepatitis, which includes hepatitis C virus (HCV) and hepatitis B virus (HBV), was blamed for nearly 90,000 deaths in 2010, while HIV claimed slightly more than 8,000 lives.

Published
14 April 2014
From
Science Daily
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible,

Published
11 April 2014
By
Keith Alcorn
International Liver Conference: activists demand affordable hepatitis C treatment

As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in low and middle-income countries. Their protest targeted Gilead whose recently-approved direct-acting antiviral, Sovaldi, sells for USD $84,000.

Published
11 April 2014
From
HepCoalition
U.S. drug industry group defends price of Gilead hepatitis drug

The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

Published
11 April 2014
From
Reuters
Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection

Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1

Published
11 April 2014
By
Liz Highleyman
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients

A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and

Published
11 April 2014
By
Liz Highleyman
88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy

Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with

Published
10 April 2014
By
Keith Alcorn
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections

A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of

Published
10 April 2014
By
Keith Alcorn
Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

Published
10 April 2014
From
Inter Press Service
PROUD UK PrEP study completes enrolment – first data give participants' background and risk factors

The pilot stage of the PROUD study – the UK's study of HIV pre-exposure prophylaxis (HIV-negative people taking HIV drugs to prevent HIV) in gay

Published
09 April 2014
By
Gus Cairns

Filter by country